Inclusion Criteria:

          -  Histologic verification of B-cell lineage leukemia or B cell non-Hodgkin lymphoma and
             evidence of relapse/refractory disease with the presence of CD19 and/or CD22 by flow
             cytometry or immunohistochemistry of bone marrow aspirate, peripheral blood or
             node/tumor biopsy

          -  Relapsed refractory disease that has failed conventional therapy and other therapies
             of higher priority

          -  Karnofsky Performance status of ≥ 60% or, if less than 16 years of age, Lansky Play
             Score of ≥ 60 (appendix II)

          -  Recovered from effects of prior therapy

          -  Peripheral blast count under 50 x 10^9/L

          -  Adequate organ function within 14 days (30 days for cardiac and pulmonary) of
             treatment start

          -  Women of childbearing potential and men should be advised and agree to practice
             effective methods of contraception during the course of study

          -  Voluntary written consent with appropriate parent/guardian consent and minor
             information sheet for participants < 18 years of age

        Exclusion Criteria:

          -  Presence of leukemic or infectious pulmonary parenchymal disease

          -  Presence of active CNS leukemia

          -  Presence of any uncontrolled systemic infection

          -  Documented uncontrolled seizure disorder- a seizure disorder controlled with
             medication

          -  Active neurologic disorder - peripheral neuropathy alone does not exclude a patient

          -  Active Hepatitis B or Hepatitis C (virus detectable by PCR)

          -  Documented penicillin or cephalosporin allergies

          -  Pregnant or lactating